Aegle Therapeutics Corp. Announces First Patient Dosed in Phase I/IIa Clinical Trial Administering a Novel Extracellular Vesicle Therapy

Aegle Therapeutics Corp. announced the first patient has been dosed in the Phase I/IIa clinical trial of AGLE-102™ for the treatment of severe second-degree burns.